• Citing Article List

    The journal uses Crossref Cited-by service counts times cited of published articles. Cited-by allows Crossref members to find out who is citing their content. This is the Citing Article List of “Current strategies for the design of PROTAC linkers: a critical review”.
    No. Publication Date Citing Article
    1 2022 Federica Pedrucci, Claudia Pappalardo, Giovanni Marzaro, Nicola Ferri, Alberto Ferlin, Luca De Toni. Proteolysis Targeting Chimeric Molecules: Tuning Molecular Strategies for a Clinically Sound Listening, International Journal of Molecular Sciences. 2022; 23: 6630.  https://doi.org/10.3390/ijms23126630
    2 2022 Jyotsana Madan, Vijay Kamal Ahuja, Kamal Dua, Susanta Samajdar, Murali Ramchandra, Sanjeev Giri. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras, BioDrugs. 2022; 36: 609.  https://doi.org/10.1007/s40259-022-00551-9
    3 2022 Miklós Békés, David R. Langley, Craig M. Crews. PROTAC targeted protein degraders: the past is prologue, Nature Reviews Drug Discovery. 2022; 21: 181.  https://doi.org/10.1038/s41573-021-00371-6
    4 2022 Markus Fleck, Michael Müller, Noah Weber, Christopher Trummer. Decoupled coordinates for machine learning-based molecular fragment linking, Machine Learning: Science and Technology. 2022; 3: 015029.  https://doi.org/10.1088/2632-2153/ac50fc
    5 2022 Guangyan Du, Jie Jiang, Nathaniel J. Henning, Nozhat Safaee, Eriko Koide, Radosław P. Nowak, Katherine A. Donovan, Hojong Yoon, Inchul You, Hong Yue, Nicholas A. Eleuteri, Zhixiang He, Zhengnian Li, Hubert T. Huang, Jianwei Che, Behnam Nabet, Tinghu Zhang, Eric S. Fischer, Nathanael S. Gray. Exploring the target scope of KEAP1 E3 ligase-based PROTACs, Cell Chemical Biology. 2022;   https://doi.org/10.1016/j.chembiol.2022.08.003
    6 2022 Diego García Jiménez, Matteo Rossi Sebastiano, Maura Vallaro, Valentina Mileo, Daniela Pizzirani, Elisa Moretti, Giuseppe Ermondi, Giulia Caron. Designing Soluble PROTACs: Strategies and Preliminary Guidelines, Journal of Medicinal Chemistry. 2022; acs.jmedchem.2c00201.  https://doi.org/10.1021/acs.jmedchem.2c00201
    7 2022 Cheng-Liang Zhu, Xiaomin Luo, Tian Tian, Zijian Rao, Hanlin Wang, Zhesheng Zhou, Tian Mi, Danni Chen, Yongjin Xu, Yizhe Wu, Jinxin Che, Yubo Zhou, Jia Li, Xiaowu Dong. Structure-based rational design enables efficient discovery of a new selective and potent AKT PROTAC degrader, European Journal of Medicinal Chemistry. 2022; 238: 114459114459.  https://doi.org/10.1016/j.ejmech.2022.114459
    8 2022 Jenny Desantis, Andrea Mammoli, Michela Eleuteri, Alice Coletti, Federico Croci, Antonio Macchiarulo, Laura Goracci. PROTACs bearing piperazine-containing linkers: what effect on their protonation state?, RSC Advances. 2022; 12: 21968.  https://doi.org/10.1039/D2RA03761K
    9 2021 Chiara Tarantelli, Eleonora Cannas, Hillarie Ekeh, Carmelo Moscatello, Eugenio Gaudio, Luciano Cascione, Sara Napoli, Cesare Rech, Andrea Testa, Chiara Maniaci, Andrea Rinaldi, Emanuele Zucca, Anastasios Stathis, Alessio Ciulli, Francesco Bertoni. The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type, Exploration of Targeted Anti-tumor Therapy. 2021; 2: 586.  https://doi.org/10.37349/etat.2021.00065
    10 2022 Olga Bakulina, Alexander Sapegin, Alexander S. Bunev, Mikhail Krasavin. Synthetic approaches to constructing proteolysis targeting chimeras (PROTACs), Mendeleev Communications. 2022; 32: 419.  https://doi.org/10.1016/j.mencom.2022.07.001
    11 2022 Jiacheng Li, Ting Liu, Yuanli Song, Mingyu Wang, Liping Liu, Hongwen Zhu, Qi Li, Jin Lin, Hualiang Jiang, Kaixian Chen, Kehao Zhao, Mingliang Wang, Hu Zhou, Hua Lin, Cheng Luo. Discovery of Small-Molecule Degraders of the CDK9-Cyclin T1 Complex for Targeting Transcriptional Addiction in Prostate Cancer, Journal of Medicinal Chemistry. 2022; 65: 11034.  https://doi.org/10.1021/acs.jmedchem.2c00257
    12 2021 Hannah Kiely-Collins, Georg E. Winter, Gonçalo J.L. Bernardes. The role of reversible and irreversible covalent chemistry in targeted protein degradation, Cell Chemical Biology. 2021; 28: 952.  https://doi.org/10.1016/j.chembiol.2021.03.005
    13 2021 Olga D. Jarosińska, Stefan G. D. Rüdiger. Molecular Strategies to Target Protein Aggregation in Huntington’s Disease, Frontiers in Molecular Biosciences. 2021; 8: 769184.  https://doi.org/10.3389/fmolb.2021.769184
    14 2021 Ying Wang, Isabella Haight, Rishi Gupta, Anil Vasudevan. What is in Our Kit? An Analysis of Building Blocks Used in Medicinal Chemistry Parallel Libraries, Journal of Medicinal Chemistry. 2021; 64: 17115.  https://doi.org/10.1021/acs.jmedchem.1c01139
    15 2022 Ruth Nussinov, Mingzhen Zhang, Ryan Maloney, Yonglan Liu, Chung-Jung Tsai, Hyunbum Jang. Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs, Journal of Molecular Biology. 2022; 434: 167569167569.  https://doi.org/10.1016/j.jmb.2022.167569
    16 ,   https://doi.org/
    17 2022 Arvind Negi, Anne Sophie Voisin‐Chiret. Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐x L Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches , ChemBioChem. 2022; 23:   https://doi.org/10.1002/cbic.202100689
    18 2022 Bohan Ma, Yizeng Fan, Dize Zhang, Yi Wei, Yanlin Jian, Donghua Liu, Zixi Wang, Yang Gao, Jian Ma, Yule Chen, Shan Xu, Lei Li. De Novo Design of an Androgen Receptor DNA Binding Domain‐Targeted peptide PROTAC for Prostate Cancer Therapy, Advanced Science. 2022; 2201859.  https://doi.org/10.1002/advs.202201859
    19 2021 Martin Reynders, Dirk Trauner. Optical control of targeted protein degradation, Cell Chemical Biology. 2021; 28: 969.  https://doi.org/10.1016/j.chembiol.2021.05.010
    20 2022 Vasanthanathan Poongavanam, Yoseph Atilaw, Stephan Siegel, Anja Giese, Lutz Lehmann, Daniel Meibom, Mate Erdelyi, Jan Kihlberg. Linker-Dependent Folding Rationalizes PROTAC Cell Permeability, Journal of Medicinal Chemistry. 2022; acs.jmedchem.2c00877.  https://doi.org/10.1021/acs.jmedchem.2c00877
    21 2021 Gabriel LaPlante, Wei Zhang. Targeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors, Cancers. 2021; 13: 3079.  https://doi.org/10.3390/cancers13123079
    22 2022 Alberto Juan, María del Mar Noblejas-López, María Arenas-Moreira, Carlos Alonso-Moreno, Alberto Ocaña. Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles, Frontiers in Cell and Developmental Biology. 2022; 9: 805336.  https://doi.org/10.3389/fcell.2021.805336
    23 2022 Fabian Fischer, Leandro A Alves Avelar, Laoise Murray, Thomas Kurz. Designing HDAC-PROTACs: lessons learned so far, Future Medicinal Chemistry. 2022; 14: 143.  https://doi.org/10.4155/fmc-2021-0206
    24 2022 Chaoguo Cao, Ming He, Liguo Wang, Yuna He, Yu Rao. Chemistries of bifunctional PROTAC degraders, Chemical Society Reviews. 2022; 51: 7066.  https://doi.org/10.1039/D2CS00220E
    25 2022 Izidor Sosič, Aleša Bricelj, Christian Steinebach. E3 ligase ligand chemistries: from building blocks to protein degraders, Chemical Society Reviews. 2022; 51: 3487.  https://doi.org/10.1039/D2CS00148A
    26 2021 Giuseppe Ermondi, Diego Garcia-Jimenez, Giulia Caron. PROTACs and Building Blocks: The 2D Chemical Space in Very Early Drug Discovery, Molecules. 2021; 26: 672.  https://doi.org/10.3390/molecules26030672
    27 2022 Tian Niu, Kailin Li, Li Jiang, Zhesheng Zhou, Ju Hong, Xuankun Chen, Xiaowu Dong, Qiaojun He, Ji Cao, Bo Yang, Cheng-Liang Zhu. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor, European Journal of Medicinal Chemistry. 2022; 228: 114012114012.  https://doi.org/10.1016/j.ejmech.2021.114012
    28 2022 Hanqiao Xu, Takashi Kurohara, Reina Takano, Hidetomo Yokoo, Norihito Shibata, Nobumichi Ohoka, Takao Inoue, Mikihiko Naito, Yosuke Demizu. Development of Rapid and Facile Solid‐Phase Synthesis of PROTACs via a Variety of Binding Styles, ChemistryOpen. 2022; 11:   https://doi.org/10.1002/open.202200131
    29 2022 Charles E. Hendrick, Jeff R. Jorgensen, Charu Chaudhry, Iulia I. Strambeanu, Jean-Francois Brazeau, Jamie Schiffer, Zhicai Shi, Jennifer D. Venable, Scott E. Wolkenberg. Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation, ACS Medicinal Chemistry Letters. 2022; 13: 1182.  https://doi.org/10.1021/acsmedchemlett.2c00124
    30 2021 Aleša Bricelj, Yuen Lam Dora Ng, Dominic Ferber, Robert Kuchta, Sina Müller, Marius Monschke, Karl G. Wagner, Jan Krönke, Izidor Sosič, Michael Gütschow, Christian Steinebach. Influence of Linker Attachment Points on the Stability and Neosubstrate Degradation of Cereblon Ligands, ACS Medicinal Chemistry Letters. 2021; 12: 1733.  https://doi.org/10.1021/acsmedchemlett.1c00368
    31 2021 Yingxin Lu, Danwen Sun, Donghuai Xiao, Yingying Shao, Mingbo Su, Yubo Zhou, Jia Li, Shulei Zhu, Wei Lu. Design, Synthesis, and Biological Evaluation of HDAC Degraders with CRBN E3 Ligase Ligands, Molecules. 2021; 26: 7241.  https://doi.org/10.3390/molecules26237241
    32 2022 Marine C. Aublette, Tom A. Harrison, Elizabeth J. Thorpe, Morgan S. Gadd. Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases, Bioorganic & Medicinal Chemistry Letters. 2022; 64: 128636128636.  https://doi.org/10.1016/j.bmcl.2022.128636
    33 2021 Kunal Nepali, Jing-Ping Liou. Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends, Journal of Biomedical Science. 2021; 28: 27.  https://doi.org/10.1186/s12929-021-00721-x
    34 2022 Xingui Liu, Alexia F. Kalogeropulou, Sofia Domingos, Nikolai Makukhin, Raja S. Nirujogi, Francois Singh, Natalia Shpiro, Anton Saalfrank, Esther Sammler, Ian G. Ganley, Rui Moreira, Dario R. Alessi, Alessio Ciulli. Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood–Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2, Journal of the American Chemical Society. 2022; 144: 16930.  https://doi.org/10.1021/jacs.2c05499
    35 ,   https://doi.org/
    36 ,   https://doi.org/
    37 2021 Fanwang Meng, Zhongjie Liang, Kehao Zhao, Cheng Luo. Drug design targeting active posttranslational modification protein isoforms, Medicinal Research Reviews. 2021; 41: 1701.  https://doi.org/10.1002/med.21774
    38 2022 Zubair Anwar, Muhammad Shahzad Ali, Antonio Galvano, Alessandro Perez, Maria La Mantia, Ihtisham Bukhari, Bartlomiej Swiatczak. PROTACs: The Future of Leukemia Therapeutics, Frontiers in Cell and Developmental Biology. 2022; 10: 851087.  https://doi.org/10.3389/fcell.2022.851087